Harnal Indication:

Used in the treatment of signs and symptoms of benign prostatic hyperplasia.

Harnal Mechanism Of Action:

Harnal is a selective antagonist at alpha-1A and alpha-1B-adrenoceptors in the prostate, prostatic capsule, prostatic urethra, and bladder neck. At least three discrete alpha1-adrenoceptor subtypes have been identified: alpha-1A, alpha-1B and alpha-1D; their distribution differs between human organs and tissue. Approximately 70% of the alpha1-receptors in human prostate are of the alpha-1A subtype. Blockage of these receptors causes relaxation of smooth muscles in the bladder neck and prostate.

Harnal Drug Interactions:

Not Available

Harnal Food Interactions:

Not Available

Harnal Generic Name:


  • Not Available

Drug Type:

Small Molecule; Approved


Absorption of tamsulosin HCI from capsules 0.4 mg is essentially complete (>90%) following oral administration under fasting conditions.

Toxicity (Overdose):

LD50 = 650 mg/kg (in rats)

Protein Binding:



Tamsulosin HCI is extensively metabolized by cytochrome P450 enzymes in the liver, however, the pharmacokinetic profile of the metabolites in humans has not been established.

Half Life:

5-7 hours

Dosage Forms of Harnal:

Tablet, extended release Oral
Capsule, extended release Oral

Chemical IUPAC Name:


Organisms Affected:

Humans and other mammals

Harnal to general, pharmacology

General, pharmacology..